National Alzheimer's Disease Awareness Month

Dear Research Advocate, Earlier this week, we held our Post-Election Briefing with a terrific panel featuring national public health leader Dr. Georges Benjamin, award-winning journalist Frank Sesno, and Capitol Hill veterans Cybele Bjorklund and Pete Kirkham. Through the lens of science and public health, we discussed the election results, the lame duck Congress, the upcoming 117th Congress, and a future Biden Administration. What surprised the panelists the most about the election: the high levels of voter participation despite the pandemic. Another area of consensus: the election results provide a crucial opportunity to elevate science and to rebuild our public health infrastructure ,...
Despite the best efforts of scientists and researchers, clinical trials on Alzheimer’s therapies have had a 99% failure rate and it has been 14 years since the Food and Drug Administration approved any Alzheimer’s-related medication. Like millions of others whose families are personally affected by Alzheimer’s disease, I am increasingly concerned that the medical, scientific, and advocacy communities are disproportionately focused on the hope that a blockbuster drug will suddenly emerge from a biopharmaceutical laboratory. This is not to say that increased investments in research should not be our foremost priority. NIH funding for Alzheimer’s-related research still lags well behind the...

Sidebar Quote

Public sentiment is everything. With public sentiment, nothing can fail; without it nothing can succeed.
Abraham Lincoln